BIG against breast cancer
Non-Profit & Charitable Organizations · Belgium · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Boulevard De Waterloo 76, Brussels, Brus...Phone Number
+32 24861600Revenue
$49.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About BIG against breast cancer
Breast International Group (BIG) is an organization dedicated to advancing international academic breast cancer research for over 25 years. Despite facing financial challenges leading to its planned closure by the end of 2026, BIG remains committed to ensuring the continuity of ongoing studies and the well-being of participating patients. The organization has coordinated numerous significant clinical trials aimed at improving treatment outcomes for various breast cancer types. Although BIG will cease to exist as a legal entity, its contributions to breast cancer research will have a lasting impact on the global medical community.Explore more
BIG against breast cancer Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BIG against breast cancer your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at BIG against breast cancer
Earning: See what the market has to say on BIG against breast cancer recently announced quarterly report
BIG against breast cancer, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once BIG against breast cancer has new funding data
Website visits: Recent activity has been detected on your website
Click to see if BIG against breast cancer had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if BIG against breast cancer has recently received funding, and reach out quickly before it becomes old news!
Check out if BIG against breast cancer is spiking on competitors!
Product Launch: Get notified when BIG against breast cancer launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
BIG against breast cancer is experiencing very low activity levels compared to other companies in the Organizations sector.
What does this means?
BIG against breast cancer is drawing exceptional interest within the Organizations industry, suggesting notable developments or strong market momentum, learn more about BIG against breast cancer.
BIG against breast cancer Tech Stack
A closer look at the technologies used by BIG against breast cancer
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
BIG against breast cancer News & Media
Breast International Group (BIG) Highlights Innovations and Challenges in Breast Cancer Research, Exclusive Interview by Xtalks
In an interview by Xtalks, Dr. David Cameron, Chair of the Breast International Group (BIG), shared valuable insights into the current state of breast cancer research, emphasizing the role of clinical trials and the integration of patient perspectives in research. BIG's efforts, as...POSITIVE study shows: young women with breast cancer can safely have a baby
Pausing endocrine treatment to try to get pregnant can be done without additional risk of recurrence in the short term. About 20% of women[[1]] (https://mail.google.com/mail/u/0/#m_-7615655520472916882__ftn1) with breast cancer are diagnosed in their reproductive years and for many of these women, fertility and pregnancy are priority concerns. Results of the POSITIVE (https://clinicaltrials.gov/ct2/show/NCT02308085) study, also called BIG Time for Baby, will be presented at the 2022 San AntonioEight-year data from APHINITY study show Roche’s Perjeta-based regimen continues to reduce the risk of disease returning for people with HER2-positive early breast cancer
Basel, 14 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support Unit (IJB-CTSU) and Frontier Science Foundation (FS) today announced updated data from the phase III APHINITY study in HER2-positive early breast cancer. Results at 8.4 years median follow-up (101 months) showed the continued benefit of the combination of Perjeta® (pertuzumab), Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen), versus HMay 20 = International Clinical Trials Day THEME 2022: “RECRUITMENT IN CLINICAL TRIALS”
The BIG network: Recruiting patients globally for faster progress against breast cancer On May 20, which marks International Clinical Trials Day, the Breast International Group (BIG) wishes to shine some light on the importance of recruitment in clinical trials and how global research and collaboration can save lives. Thanks to its global network of breast cancer research groups, BIG can quickly enrol 1000s of patients from around the world into large clinical trials, leading to
Read more news
Top Non-Profit & Charitable Organizations Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BIG against breast cancer
Sign Up For FreeTo access detailed company insights
Breast International Group (BIG) is an organization dedicated to advancing international academic breast cancer research for over 25 years. Despite facing financial challenges leading to its planned closure by the end of 2026, BIG remains committed to ensuring the continuity of ongoing studies and the well-being of participating patients. The organ... Read More
